- Select a blog category
This week’s blog is by a former colleague and partner with Deloitte UK, Simon Hammett who retired earlier this year after an exemplary career to pursue a number of long held ambitions. Knowing that one of his new roles was as a Trustee of Prostate Cancer UK, I asked him to share his experience by way of a blog and true to his word he has delivered as promised. In Simon’s own words:
I became a Trustee on the Board of Prostate Cancer UK in March 2016. With over twenty years’ experience in the healthcare and life sciences sector, I wanted to give something back. I have found the experience incredibly satisfying for a number of reasons.
Deloitte's recently published report, Facing the tidal wave: De-risking pharma and creating value for patients looks at how the healthcare ecosystem has become increasingly complex, strained and challenged by a responsibility to deliver better patient outcomes while managing escalating healthcare costs. One of the key issues identified in our report was that the incidence of cancer is expected to increase substantially over the next few decades, whilst the financial burden and cost to society for the disease are expected to increase significantly. A recent article by Deloitte's global life sciences leader Greg Reh considers changes to the ways in which oncology treatments are now being funded in the US, known as value-based oncology payment models, and the implications this will have for biopharma companies. This week’s blog seeks to share these insights from the US and the potential implications should European funding systems adopt similar payment models.
Last week’s World Antibiotic Awareness Week was aimed at continuing to raise the profile of importance of tackling antimicrobial resistance.1
November 14th was World Diabetes Day.i Today in the UK there are some 3.5 million people diagnosed with diabetes and 549,000 people living, unknowingly, with the condition. In 2015, diabetes cost the NHS some £10 billion, however, the real cost to the individual is the debilitating effect of the disease and the increased risk of developing life-threatening complications. People with diabetes are twice as likely to be admitted to hospital and, every day in the UK, some 65 people die prematurely from complications of diabetes. Improving the management of diabetes has significant implications for patient outcomes and reducing healthcare costs.ii This week’s blog is a personal story of living with diabetes type 1 and the impact that health technology can have on improving diabetics’ lives.
This week we launched our report Primary care today and tomorrow: Adapting to survive, which provides an update on our understanding of the developments and challenges in primary care since our first report in 2012 (Improving general practice by working differently). Since 2012, primary care providers have encountered an increasingly turbulent political and financial landscape, with a range of new pressures emerging. Workforce shortages have combined with rising patient demand, inadequate facilities and on-going under-funding.
The digital revolution, has completely transformed how we access, collect and transmit information. In the last decade the ‘internet of things’ and the increasing capacity and capability of smartphones, tablets and more recently wearables, have had a profound impact on society as a whole. Changing consumer expectations, behaviours and demand. In response, businesses are constantly adapting and innovating from contactless and online banking services to smart energy meters and now the ‘connected homes’. Our report in 2015 Connected Health: how digital technology is transforming health and social care and our more recent research for our report Vital signs: how to deliver better healthcare across Europe suggests that healthcare may in fact be at a tipping point in its digital revolution.
This week, our Deloitte public sector practice, in collaboration with Reform, published their fifth annual report – The State of the State 2016-17: Brexit and the Business of Government. The report is a unique analysis of the UK public sector and provides a compelling commentary on the big challenges it faces as the UK Government moves from an era focussed on eliminating the budget deficit, into an era of multiple and complex challenges. Specifically, the need to manage the UK's departure from the EU, drive major reforms and maintain business as usual.
This week’s blog is by our colleague, Lee Feander, a Director specialising in Life Science Supply Chain, which recently appeared in Scrip. The blog looks into new distribution models for the life science industry, and the impact that these models may have for both patients and the future of the industry.
In late 2014 we published our report Transforming care at the end-of-life: Dying well matters a subject that I feel passionate about and which I have continued to champion both through my research and also as a non-executive director in a district general hospital. Indeed, in our most recent report Vital Signs: How to deliver better healthcare across Europe, we included as one of the vital signs, palliative and end-of-life care. In this latter report we included a quote from Atul Gawande, “If end-of-life discussions were an experimental drug, the FDA would approve it”.i This week’s blog, by our colleague, Dr Anni Mekhail, recounts a patient story from her time as a resident doctor, and illustrates poignantly how having meaningful conversations with patients can help ease a very difficult time for the patient, their family and medical staff.
Over the past few decades the regulation of the safety of medical devices has remained relatively unchanged. However, today's medical devices are becoming ever more sophisticated and innovative and existing rules have not kept pace with scientific and technical developments. Moreover, the 2011 silicone breast implant scandal and produce recall of the metal-on-metal hip, highlighted serious weaknesses in the current regulatory system and strengthened the case for modernising current rules for medical devices. Following several years of negotiation, new legislation was agreed by all member countries in June 2016 and will become law in late 2019 or early 2020. This week’s blog, by Fiona Maini and Sarah Chan from our Risk and Regulatory practice explores the implications of the legislation for the medical devices industry.
It’s now nearly two years since we published our report Healthcare and Life Sciences Predictions 2020: A bold future? Since then we have had numerous conversations with clients and other stakeholders on our vision of the future. We acknowledged that our view was an optimistic one but also that the technology to delivery these predictions was already available and even being deployed, albeit not at scale. I was fascinated to read a recent article from my colleague and fellow Research Director at the US Center for Health Solutions, Sarah Thomas, on healthcare consumers’ appetite for technology enabled care and her own take on the potential ways of delivering care to people at homes. I therefore thought I would use this week’s blogs to share Sarah’s insights with our readers.